Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MTL-CEBPA by Mina Therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ): Likelihood of Approval
MTL-CEBPA is under clinical development by Mina Therapeutics and currently in Phase II for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome...